I did not say a new trial was required. Don’t be alarmist. Read my post again and I will welcome your apology for misreading it.
What I did say was that this was going to cost PAR to money to go back review and modify the trial to fix the fact 2/2 is not currently included in the design.
What are the additional costs that will arise from this modification of the par 002 trial? Are you telling me there is no cost impact involved?
DS made no such claim on whether this was going to have a financial impact or not. What she did say is that they will need to take time to review and will report back to the market.
Ann: iPPS SIGNIFICANT OA PAIN REDUCTION AT 12 MONTHS, page-78
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
-0.015(4.84%) |
Mkt cap ! $103.1M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 30.5¢ | 29.5¢ | $86.19K | 286.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 70151 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 18600 | 1 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |